Skip to main content
MyMD Logo

Significantly increasing lifespan

LEARN HOW WITH MyMD

Novel therapeutics that make an impact

MyMD in the Media

MyMD in the Media

MyMD has been featured by multiple media outlets following its merger with Akers Biosciences.

MyMD is a clinical-stage pharmaceutical company focused on the development of drug products that represent a transformation in the targeting of aging and age-related diseases; autoimmune diseases; and chronic pain, anxiety and sleep disorders. Our team has partnered with academic founders and key opinion leaders to identify synthetic therapeutics, including the first drug being designed to significantly increase human lifespan.


MyMD Pharmaceuticals Drug Candidates

MyMD is commercializing two broad drug platforms, each with its own distinct indications. MYMD-1 is a novel therapeutic shown to positively impact multiple conditions related to immunometabolic dysregulation. SUPERA-1R is a synthetic cannabidiol that offers better bioavailability and potency than botanicals. Both are protected by a robust, worldwide patent portfolio.

MYMD-1

MYMD-1 is a clinical-stage, synthetic plant alkaloid that has been shown to ameliorate immunometabolic dysregulation targeting immune cell metabolism. Its mechanism of action and efficacy in autoimmune diseases, such as Multiple Sclerosis EAE (MS) and thyroiditis, and aging mouse models have been studied through MyMD’s collaboration with several academic institutions.

Targets the cause, not the symptoms

Regulates the immuno-metabolic system through the modulation of numerous pro-inflammatory cytokines, including TNF-α, IL-6 and IL-17A. MYMD-1 is also not detrimental to cell viability and is small enough to cross the blood-brain barrier.

Multiple indications

MYMD-1 is being developed to target aging (sarcopenia) and depression in age or inflammatory-related diseases.

Scientific Publications

SUPERA-1R

SUPERA-1R is a synthetic, preclinical cannabidiol derivative that has demonstrated to effectively target CB2 receptors. As a new molecular entity (patent pending), SUPERA-1R addresses the unmet need for a synthetic CBD with enhanced bioavailability and potency so physicians may treat patients with an FDA approved drug rather than botanicals that contain impurities.

More effective than CBD

Approximately 7-8X more effective than plant-derived CBD in reducing MAO-A and MAO-B (which play a role in substance addiction) in a dose-dependent manner. It has been shown to inhibit opioid receptors and is more potent than plant-based CBD in binding to CB2 receptors.

Robust platform

SUPERA-1R is being developed to address anxiety, chronic pain, and seizures and is expected to begin human trials as a therapy for epilepsy, followed by chronic pain.

Key Personnel

MyMD brings together leading scientists, doctors, researchers and business executives. We are continuing to add clinical and scientific talent to our research and discovery team, and look forward to sharing more over the near term.

Chris Chapman, M.D.

President and Chief Medical Officer

Chris Chapman, M.D.

President and Chief Medical Officer

Founding Director of the Medical Affairs, Drug Safety and Medical Writing Departments, Quintiles

Founder and CEO, Chapman Pharmaceutical Consulting, Inc.

Adam Kaplin, M.D., Ph.D.

Adam Kaplin, M.D., Ph.D.

Chief Scientific Officer

Adam Kaplin, M.D., Ph.D.

Adam Kaplin, M.D., Ph.D.

Chief Scientific Officer

Prior Founder and Chief, Neuropsychiatric CNS Autoimmune Consultation Clinic, Johns Hopkins Multiple Sclerosis Center of Excellence, and Founder and Clinical Director, Johns Hopkins Psychiatric Esketamine Clinic

Adjunct Faculty, Departments of Psychiatry and Neurology
Johns Hopkins University School of Medicine

Paul Rivard, Esq.

Paul Rivard, Esq.

VP of Operations & General Counsel

Paul Rivard, Esq.

Paul Rivard, Esq.

VP of Operations & General Counsel

Shareholder, Banner & Witcoff
Patent Examiner, U.S. Patent and Trademark Office (1992-1998)

We’re redesigning our website

In the meantime, we want to hear from you.

Contact us or subscribe to stay up-to-date on MyMD Pharmaceuticals news and of our upcoming website launch.

Contact Us Subscribe Akers Biosciences Business Update

  • This field is for validation purposes and should be left unchanged.
  • This field is for validation purposes and should be left unchanged.